SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Jason R. Westin(The University of Texas MD Anderson Cancer Center), Laura Fogliatto(Hospital de Clínicas de Porto Alegre), Adam J. Olszewski(Memorial Hospital of Rhode Island), Michael C. Wei(The Royal Melbourne Hospital), Elicia Penuel, Hao Wu, Shen Yin, Jing Jing, Ho‐Jin Shin(Pusan National University Hospital), Won-Seog Kim(Samsung Medical Center), Song Pham(Roche (Canada))
Cited by 8
Related Papers
tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c
|Genes & Development|2000|1.3k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
|Nature Medicine|2020|593